2NA FISH GmbH, a Munich-based biotech company, has secured additional pre-seed funding led by GF BRYCK Ventures to advance its spatial RNA detection platform aimed at enhancing oncology decision support.

Information on the Target

2NA FISH GmbH is a biotech company based in Munich, Germany, specializing in the development of a next-generation spatial RNA detection platform aimed at enhancing oncology decision support. The company has recently secured additional pre-seed funding, primarily from GF BRYCK Ventures, along with a follow-on investment from existing stakeholder, Twip. This new capital will facilitate the development and validation of its innovative spatial RNA biomarker detection technology for use in both research and translational applications.

The platform from 2NA FISH integrates nanostructure-enhanced probes with established pathology workflows to produce bright and specific signals, allowing for effective multiplexing on standard fluorescence microscopes. The primary goal is to democratize spatial RNA biomarker testing, making it more accessible and applicable in everyday laboratory and pathology environments. Additionally, an AI-driven analysis application enhances quantification and cell-level insights, transforming spatial RNA data into actionable biomarker information.

Industry Overview in Germany

Germany's biotech industry is recognized as one of the fastest-growing sectors in Europe, benefitting from significant investments in research and development. The country is home to numerous innovative startups and established companies that play a pivotal rol